Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?
Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TSHA.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 23,555,648 | $105,293,747 | 1.12% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 21,700,000 | $96,999,000 | 0.95% | |
| 3. | Vestal Point Capital Ryan Wilder | 18,000,000 | $80,460,000 | +31% | 2.25% |
| 4. | Octagon Capital Advisors Ting Jia | 8,859,911 | $39,603,802 | 4.38% | |
| 5. | Siren L.L.C. Raymond Debbane | 8,829,913 | $39,469,711 | -13% | 1.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 750,000 | $2,062,500.00 | 2,841,704 | 2025-05-30 | Filing | |
| $2.25 | 1,333,333 | $2,999,999.25 | 1,333,333 | 2024-06-27 | Filing | |
| $1.63 | 100,000 | $163,000.00 | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | $14,820,000.30 | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | $350,000.10 | 999,381 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.24 | 200,000 | $1,248,000.00 | 936,410 | 2026-07-10 | Filing | |
| $4.46 | 200,000 | $892,000.00 | 1,136,410 | 2026-04-10 | Filing | |
| $4.52 | 1,655 | $7,480.60 | 1,442,131 | 2026-02-04 | Filing | |
| $4.61 | 26,918 | $124,091.98 | 1,317,389 | 2026-01-26 | Filing | |
| $4.75 | 89,132 | $423,377.00 | 1,344,307 | 2026-01-23 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 519,120 | $3,535,207 | 0.1% | |
| 2. | 45,000 | $306,450 | 0.2% | |
| 3. | 232 | $1,580 | 0% |
News See All
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best small cap stocks to buy for 10x potential. Taysha Gene Therapies, Inc.
15 Best Small Cap Stocks to Buy for 10x Potential
On May 11, Dan Niles, Niles Investment Management founder, appeared on CNBC’s ‘The Exchange’ to talk about his view on equity markets while conducting a comparison with the prior periods.
10 Best US Stocks Under $5 to Buy
Burry, who is best known for predicting the US housing crash, said that almost all conversations are focused on AI.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies First Quarter 2026 Financial Results Conference Call.
10 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds
On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended period of market uncertainty in the prior year, noting that market attention ...
9 Best Healthcare Penny Stocks to Buy According to Hedge Funds
Volatility in the equity market has been on another level in the first quarter of the year.
10 Best Multibagger Penny Stocks to Invest In
Small-cap and penny stocks are often overlooked by Wall Street as they tend to be extremely volatile.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026Taysha Gene Therapies, Inc. beats earnings expectations.
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress
TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating.
Hedge Fund Resource Center